Department of Urology, Oregon Health & Science University, Portland, Oregon.
J Urol. 2024 Nov;212(5):731-737. doi: 10.1097/JU.0000000000004162. Epub 2024 Jul 31.
Urologic surgery involving placement of an indwelling ureteral and/or urethral drain can be associated with significant catheter-related bladder discomfort causing increased postoperative morbidity and opioid medication use. We sought to assess if a single dose of oxybutynin given preoperatively reduces immediate postoperative opioid use in common pediatric urology surgeries.
This single-institution retrospective study identified pediatric patients who underwent surgery on the urinary tract with concomitant placement of a urethral and/or ureteral drain. Patients were given a single weight-based dose of oral oxybutynin in the preoperative area prior to surgery. The primary outcome was receipt of postoperative opioid medication. Multivariable regression analyses were used to assess variables associated with postoperative opioid use.
A total of 134 patients were included in our final study population with 42 receiving oxybutynin and 92 who did not. There was no statistical difference between the groups in terms of age, procedure type, anesthesia block, postoperative drain, or intraoperative morphine milligram equivalents per kilogram. Patients who received oxybutynin preoperatively had a decrease in postoperative opioid use (19%) compared to those who did not receive oxybutynin (47%). On multivariable logistic regression analysis, preoperative oxybutynin was associated with a 77% reduced risk of receiving postoperative opioid (odds ratio 0.23, [95% CI 0.09-0.56], < .001).
For pediatric patients with an indwelling urinary drain after urologic surgery, a single preoperative dose of oxybutynin was significantly associated with lower postoperative utilization of opioids. This relatively low-risk intervention can be easily implemented.
泌尿科手术中留置输尿管和/或尿道引流管可能会引起明显的与导管相关的膀胱不适,导致术后发病率和阿片类药物使用增加。我们试图评估术前给予单剂量奥昔布宁是否可以减少常见小儿泌尿科手术的术后即刻阿片类药物使用。
这项单机构回顾性研究确定了接受经尿道手术并同时放置尿道和/或输尿管引流管的小儿患者。患者在手术前的术前区域给予单次基于体重的口服奥昔布宁剂量。主要结果是接受术后阿片类药物。使用多变量回归分析评估与术后阿片类药物使用相关的变量。
共有 134 名患者纳入我们的最终研究人群,其中 42 名接受奥昔布宁治疗,92 名未接受奥昔布宁治疗。两组在年龄、手术类型、麻醉阻滞、术后引流管或术中吗啡毫克当量/千克方面无统计学差异。与未接受奥昔布宁治疗的患者相比,术前接受奥昔布宁治疗的患者术后阿片类药物使用减少(19%)。在多变量逻辑回归分析中,术前奥昔布宁与接受术后阿片类药物的风险降低 77%相关(比值比 0.23,[95%CI 0.09-0.56],<0.001)。
对于泌尿科手术后留置导尿管的小儿患者,术前给予单剂量奥昔布宁与术后阿片类药物使用率显著降低相关。这种相对低风险的干预措施易于实施。